Sutent Drug Interactions

Drugs that may increase sunitinib plasma concentrations: Concomitant administration of sunitinib with the strong CYP3A4 inhibitor ketoconazole resulted in a 49% and 51% increase of the complex [sunitinib + primary active metabolite] C_max and AUC_0-∞ values, respectively, after a single dose of sunitinib in healthy volunteers.
Administration of sunitinib with strong inhibitors of the CYP3A4 family (e.g., ritonavir, itraconazole, erythromycin, clarithromycin, grapefruit juice) may increase sunitinib concentrations. Concomitant administration with inhibitors should therefore be avoided, or the selection of an alternate concomitant medication with no, or minimal potential to inhibit CYP3A4 should be considered. If this is not possible, the dosage of sunitinib may need to be reduced (see Dosage & Administration).
Drugs that may decrease sunitinib plasma concentrations: Concomitant use of sunitinib with the CYP3A4 inducer rifampin resulted in a 23% and 46% reduction of the complex [sunitinib + primary active metabolite] C_max and AUC_0-∞ values, respectively, after a single dose of sunitinib in healthy volunteers.
Administration of sunitinib with strong inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, phenobarbital or Hypericum perforatum also known as St. John's Wort) may decrease sunitinib concentrations. Concomitant administration with inducers should therefore be avoided, or selection of an alternate concomitant medication with no, or minimal potential to induce CYP3A4 should be considered. If this is not possible, the dosage of sunitinib may need to be increased (see Dosage & Administration).